Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

LifePoint Health (LPNT) Q1 Earnings Beat, Revenues Miss

Published 05/06/2018, 09:43 PM
Updated 07/09/2023, 06:31 AM

LifePoint Health, Inc. (NASDAQ:LPNT) reported earnings of $1.22 per share in first-quarter 2018, beating the Zacks Consensus Estimate by 10.9%. Also, the figure increased 14% year over year.

Operational Update

Revenues of $1.6 billion missed the Zacks Consensus Estimate by 0.7% and declined 1.7% year over year.

Same-hospital revenues increased 0.4% year over year to $1.6 billion. This increase was led by a 2.6% rise in same-hospital revenues per equivalent admission, partially offset by a 2.2% decrease in same-hospital equivalent admissions.

LifePoint Health, Inc. Price, Consensus and EPS Surprise

Adjusted EBITDA for the quarter ended Mar 31, 2018, was $188.5 million, down 3.6% year over year.

Equivalent admissions declined 4.7% year over year to 171,272 and revenue per equivalent admission was up 3% year over year to $9,358.

Total expenses of $1.61 billion increased 4.6% year over year, led by higher other operating expenses.

At the end of the first quarter, the company had 71 hospitals compared with 72 hospitals in the year-ago quarter.

Margins for the quarter were 11.8%, up 20 basis points sequentially. The margin expansion includes improvements in the class of 2016 hospitals and benefits from additional cost management initiatives.

Financial Update

As of Mar 31, 2018, the company had total assets of $6.26 billion, down 0.5% year over year.

Cash and cash equivalents totaled $140 million, up 25% year over year.
As of Mar 31, 2018, long-term debt increased 0.6% to $2.89 billion from year-end 2016.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Net cash provided by operating activities totaled $100.6 million, up 9.7% year over year, led by decreases in the amount and timing of payments for self-insurance claims and taxes. These improvements were partially offset by increases in the amount and timing of payments for accounts payable and accrued salaries.

The company invested $56.2 million in capital expenditures during the first quarter with its full year expected spend ranges from $475 million to $500 million.

Share Repurchase Update

The company repurchased 625,000 shares of its common stock for $30 million in the first quarter.

Business Update

During the reported quarter, the company entered into an agreement to sell the three hospitals in the State of Louisiana – Mercy Regional Medical Center in Ville Platte, Acadian Medical Center, a campus of Mercy Regional in Eunice, and Minden Medical Center in Minden, LA.

Zacks Rank & Performance of Peers

LifePoint Health presently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Among the other firms in the medical sector that have reported their first-quarter earnings so far, the bottom line at Centene Corp. (NYSE:CNC) , Anthem Inc (NYSE:ANTM) and UnitedHealth Group Inc. (NYSE:UNH) beat their respective Zacks Consensus Estimate.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report

Anthem, Inc. (ANTM): Free Stock Analysis Report

Centene Corporation (CNC): Free Stock Analysis Report

LifePoint Health, Inc. (LPNT): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.